Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4A | P27815 | 15/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 15/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 15/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 15/20 | 0.39 |
| ▸ | WDR5 | P61964 | 1/20 | 0.37 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11096376 | 0.82 | PDE4A (0.36) | PDE4APDE4BPDE4CPDE4DWDR5 | |
| SCHEMBL11091127 | 0.82 | PDE4B (0.54) | PDE4APDE4BPDE4CPDE4DMEN1 | |
| SCHEMBL11826260 | 0.81 | PSEN1 (0.37) | PDE4APDE4BPDE4CPDE4DPSEN1 | |
| SCHEMBL6604510 | 0.80 | LMNA (0.39) | PDE4APDE4BPDE4CPDE4DPSEN1 | |
| SCHEMBL6601490 | 0.79 | PDE4B (0.34) | PDE4APDE4BPDE4CPDE4DPSEN1 | |
| SCHEMBL6618935 | 0.78 | PDE4A (0.51) | PDE4APDE4BPDE4CPDE4DWDR5 | |
| SCHEMBL4241620 | 0.78 | PSEN1 (0.35) | PDE4APDE4BPDE4CPDE4DPSEN1 | |
| SCHEMBL11096494 | 0.78 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL8022068 | 0.77 | ADRA1A (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4430870 | 0.77 | PSEN1 (0.44) | PDE4APDE4BPDE4CPDE4DPSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1463718-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | Incyte San Diego Incorporated (US) | 2004-10-06 | — | — | EP | disclosed |
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | INCYTE SAN DIEGO INCORPORATED | 2004-05-20 | — | — | US | disclosed |
| WO-2003050098-A1 | 2-SUBSTITUTED THIAZOLIDINONE AND OXAZOLIDINONE DERIVATIVES FOR THE INHIBITION OF PHOSPHATASES AND THE TREATMENT OF CANCER | INCYTE SAN DIEGO INCORPORATED (US) | 2003-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040097566-A1 | 2-Substituted thiazolidinone and oxazolidinone derivatives for the inhibition of phosphatases and the treatment of cancer | PTPA, PTPRC, PTPRCAP | PDE4A 715/4885PDE4B 936/4885PDE4C 665/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.